10x Genomics
390 hedge funds and large institutions have $4.91B invested in 10x Genomics in 2026 Q2 according to their latest regulatory filings, with 100 funds opening new positions, 97 increasing their positions, 140 reducing their positions, and 33 closing their positions.
421% more call options, than puts
Call options by funds: $26.8M | Put options by funds: $5.14M
203% more first-time investments, than exits
New positions opened: 100 | Existing positions closed: 33
85% more capital invested
Capital invested by funds: $2.66B → $4.91B (+$2.26B)
18% more funds holding
Funds holding: 330 → 390 (+60)
3.46% more ownership
Funds ownership: 106.4% → 109.86% (+3.5%)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
31% less repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 140
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$115M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$53.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$48.6M |
| 4 |
ACM
Anomaly Capital Management
New York
|
+$22.7M |
| 5 |
Jane Street
New York
|
+$19.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$51.1M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$44.9M |
| 3 |
CC
Casdin Capital
New York
|
-$32.1M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$24M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
-$23.9M |
TXG Hedge Fund Activity: Q2 2026 in Review
390 of the 8,286 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q2 2026, worth a combined $4.91B — up 85% from $2.66B a quarter earlier.
Buyers outnumbered sellers: 100 funds opened new TXG positions and 33 closed out — a net gain of 67 holders — while 97 added to existing stakes and 140 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $115M. The largest seller was Millennium Management, cutting an estimated $51.1M.
- 390 institutional investors held 10x Genomics (TXG) as of Q2 2026, up from 330 in Q1 2026.
- Funds reported $4.91B of 10x Genomics stock for Q2 2026, up 85% quarter-over-quarter.
- 100 funds opened new 10x Genomics positions in Q2 2026 and 33 closed out, a net change of +67 holders.
- The largest 10x Genomics buyer in Q2 2026 was T. Rowe Price Associates, an estimated $115M added.
- The largest 10x Genomics seller in Q2 2026 was Millennium Management, an estimated $51.1M sold.
Based on aggregated 13F filings for Q2 2026.